Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13662807 | 0.78 | PDE10A (0.38) | NOS1 | |
| SCHEMBL13615892 | 0.76 | RAB9A (0.34) | — | |
| SCHEMBL12680079 | 0.76 | CDC25A (0.40) | NOS3NOS1NOS2 | |
| SCHEMBL13659780 | 0.75 | ADORA3 (0.40) | NOS3NOS1NOS2 | |
| SCHEMBL20390477 | 0.75 | — | — | |
| SCHEMBL20390802 | 0.74 | SREBF2 (0.34) | NOS3NOS2 | |
| SCHEMBL12248377 | 0.71 | ADORA3 (0.39) | — | |
| SCHEMBL179350 | 0.70 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL30502967 | 0.70 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL13623572 | 0.70 | CCR1 (0.50) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | NOS3 2152/4885NOS1 2996/4885NOS2 1875/4885 |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | NOS3 2152/4885NOS1 2996/4885NOS2 1875/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | NOS3 1939/4885NOS1 2843/4885NOS2 1639/4885 |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | NOS3 2152/4885NOS1 2996/4885NOS2 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.